Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele-Reference-Cited by-同舟云学术

Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele

Published:2021-08-20 Issue:6 Volume:14 Page:2521-2531
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Bordin Andriguetti Natália¹^ORCID,Van Schalkwyk Helena Katherina¹^ORCID,Barratt Daniel Thomas²^ORCID,Tucci Joseph³^ORCID,Pumuye Paul⁴^ORCID,Somogyi Andrew Alexander¹^ORCID

Affiliation:

1. Discipline of Pharmacology Adelaide Medical School University of Adelaide Adelaide SA Australia

2. Discipline of Physiology Adelaide Medical School University of Adelaide Adelaide SA Australia

3. Department of Pharmacy & Biomedical Sciences La Trobe University Bendigo Campus Bendigo Victoria Australia

4. School of Medicine and Health Sciences University of Papua New Guinea National Capital District Papua New Guinea

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13120

Reference50 articles.

1. PharmGKB summary

2. Efavirenz

3. World Health Organization.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.2013.https://www.who.int/hiv/pub/guidelines/arv2013/art/artadults/en/. Accessed November 14 2020.

4. World Health Organization.Update of recommendations on first‐ and second‐line antiretroviral regimens.2019.https://apps.who.int/iris/bitstream/handle/10665/325892/WHO‐CDS‐HIV‐19.15‐eng.pdf?ua=1. Accessed November 30 2020.

5. AIDSMAP.Dolutegravir recommended for all in new World Health Organization guidelines.2019.https://www.aidsmap.com/news/jul‐2019/dolutegravir‐recommended‐all‐new‐world‐health‐organization‐guidelines. Accessed December 2 2020.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia;CPT: Pharmacometrics & Systems Pharmacology;2023-03-23

2. Effects of rifampicin, CYP2B6 and ABCB1 polymorphisms on efavirenz plasma concentration in Chinese patients living with HIV and tuberculosis;International Journal of STD & AIDS;2022-11-10

3. Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen;Pharmacogenetics and Genomics;2022-06-22

4. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort;British Journal of Clinical Pharmacology;2022-05-25